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Abstract
Purpose The purpose of this study was to evaluate midkine,
multipotential cytokine, and growth factor in colorectal can-
cer (CRC) stratified by tumor location.
Methods Midkine was assessed immunoenzymatically in
paired cancerous and noncancerous tissues from 53 CRCs
and referred to CRC stage, tumor location, and size, and
circulating cytokine levels.
Results Midkine was higher in cancerous versus noncancer-
ous tissue in 98 % cases (424.2 vs. 31.1 pg/mg, p<0.0001).
Mean fold increase was 30.1; in 72.5 %, the relative increase
was over fivefold. Midkine upregulation was more pro-
nounced in colon than in rectum (fold increase: 36.6 vs.
12.7, p00.005) due to higher midkine level in noncancerous
rectal than colonic tissue (45.5 vs. 26.2 pg/mg, p00.074).
Tumor location affected midkine association with CRC
stage. Midkine fold change was higher in advanced stages
of rectal cancers (16.8 vs. 5.3, respectively in III/IV vs. I/II,
p00.013), while it tended to be lower in colonic ones (25.3
vs. 47.8, p00.134). In addition, fold change in midkine level
was higher in rectal N1 than N0 cancers (17.3 vs. 16.5, p0
0.032), while it tended to be lower in colonic cancers (23.6
vs. 50.1, p00.085). Midkine negatively correlated with tu-
mor size (r00.40, p00.017), while it tended to positively
correlate with its serum levels (r00.45, p00.081).
Conclusions Midkine is differently expressed in tumors
arising from colonic and rectal mucosa, where it may play
diverse roles in carcinogenesis. High midkine expression in
noncancerous rectal mucosa might contribute to, a charac-
teristic for rectal cancers, higher incidence of local recur-
rence. Divergent expression of midkine and its association
pattern ought to be taken into account while designing
midkine-directed therapies for CRC.
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Introduction
Colorectal cancer (CRC) is a malignant tumor arising from
the inner wall of large intestine. Worldwide, it is the third
cause of cancer deaths in women and fourth in men and the
second and the third most frequently diagnosed cancer in
women and men, respectively. Unlike in USA and Western
Europe, CRC incidence in Eastern European countries is
increasing probably as a result of “westernization” of a
lifestyle [1].
Individual segments of the colon differ with respect to their
embryological origin, innervation, blood supply, lymphatic
drainage, histology, physiological function, and content. It
seems logical that tumors that arise from proximal and distal
colon or, taking into account differences in histology and
metabolism, from proximal and distal colon and rectum ought
to be treated as distinct entities [2]. Indeed, it has been in-
creasingly recognized that tumor location determines risk and
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protective factors, mechanisms promoting the disease
progression, recurrence pattern, prognosis, and effective-
ness of various treatment strategies [2–5]. Unveiling
differences in cancer-related molecular patterns with respect
to tumor location might aid future targeted therapies for
CRC.
Midkine is a multifunctional cytokine predominantly
expressed during embryogenesis, while in adult organisms,
its expression is restricted to several organs, intestine, among
others. However, midkine expression is resumed during in-
flammation, tissue repair, and carcinogenesis. Midkine dis-
plays a number of activities that might be relevant for cancer
development, e.g., it has been demonstrated to act as a mito-
gen, an antiapoptotic, and angiogenic factor, a chemoattractant
and haptotactic factor, an immunomodulator, and an inductor
of synthesis of several cytokines and growth factors, such as
IL-8, TGF-β, MIP-2, and MCP-1 [6, 7]. Data on midkine in
CRC are scanty and focused on its involvement in colonic
neoplastic transformation [8–12], while data on cytokine lev-
els in CRC are missing. Possible midkine contribution to
divergence in molecular patterns involved in promoting tumor
progression between CRCwith different location has not been
evaluated before as well. Hence, the aim of our study was to
examine protein level of midkine in tumor versus normal
colorectal tissue and relate it to the disease progression, tumor
location, and circulating levels of cytokine.
Materials and methods
Patients
A group of 53 patients admitted between 2005 and 2008 to the
Department of Gastrointestinal and General Surgery of
Wroclaw Medical University for curative resection of histo-
pathologically confirmed adenocarcinoma of the colon has
been enrolled in current study. Open colectomy (right hemi-
colectomy n010; transverse colectomy n07; left hemicolec-
tomy n03; sigmoidectomy n019; rectectomy n014) was
performed in 27 men and 26 women, mean age of 67.8 (range,
36–87). Resected tumors were staged pathologically according
to the guidelines of the UICC TNM [13] system. There were
11 cases of T2, 10 cases of T3, and 30 cases of T4, and in two
cases, T was not established (Tx); there were 25 cases of N0,
22 cases of N1, three of N2, and three of Nx; no distant
metastases were found in 47 cases, hepatic metastases in five
cases, and in one, M status was uncertain. When grouped, we
had eight patients with stage I, 17 with stage II, 20 with stage
III, five with stage IV, and in three, the disease stage could not
be assessed. The tumor was located in rectum in 14 cases, in
colon in 36 cases (in ascending colon in seven, in transverse
colon in seven, in descending colon in three, and in sigmoid
colon in 19 cases), and in cecum in three cases. Two patients
were excluded from the analysis following pathological exam-
ination owing to cancerous tissue present in resection margins.
The study protocol was approved by the Medical Ethics
Committee of Wroclaw Medical University, Wroclaw,
Poland, and the study was conducted in accordance with
the Helsinki Declaration of 1975, as revised in 1983, and an
informed consent has been obtained from all patients.
Analytical methods
A paired tissue samples, one representing tumor and the
other noncancerous tissue from the same location (resection
margin), have been collected postoperatively for each pa-
tient, snap frozen, and stored at −45°C until examination.
Frozen tissues (∼0.37 g) were placed in 10 mM Tris–HCl,
pH 7.2 buffer 1:2 (w/v) and homogenized using a Potter
homogenizer. Following centrifugation (10 min, 1,850×g,
4°C), supernatants were collected and used for subsequent
midkine and protein evaluations. Additionally, serum sam-
ples (blood collected by venipuncture prior to surgery, clot-
ted for 30 min, and centrifuged 10 min, 900×g, RT) were
available for a subset of 19 patients. Midkine concentrations
in tissue homogenates and serum samples were measured
with by an enzyme double-antibody indirect immunoassay
using Human Midkine ELISA provided by Biovendor
(Brno–Modřice, Czech Republic) according to manufac-
turer’s instructions. An intra-assay coefficient of variation
(CV) for this assay is 4.5 % and inter-assay CV is 6.3 %,
while the test sensitivity is 33 pg/ml. Protein concentration
in tissue homogenates was measured using Bradford method
[14] with Bio-Rad Protein Assay (Bio-Rad Laboratories
GmbH, Munchen, Germany) with bovine serum albumin
as the reference. Midkine concentration was expressed in
picograms per milligram of total protein.
Statistical analysis
Data distribution was tested using the Kolmogorov–Smirnov
normality test and homogeneity of variances using Levene’s
test. Data on midkine in cancerous tissue were normally
distributed, while those in adjacent noncancerous tissue re-
quired logarithmic transformation; both are presented as
means with 95 % confidence interval. Differences in midkine
level between cancerous and normal tissues were analyzed
using t -test for paired samples. Differences in midkine level
or fold change in groups stratified by the disease stage or
tumor location were examined using t test for independent
samples (with Welch correction in case of unequal variances)
and one-way ANOVA. Correlation analysis was conducted
using Pearson correlation (r) test, following removal of outly-
ing observations detected using Tukey test (two outliers
detected). All tests were two-sided and p≤0.05 were consid-
ered statistically significant. Entire statistical analysis was
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conducted using MedCalc® version 12.1.0.0 (Mariakerke,
Belgium).
Results
Midkine in normal and tumor tissue
We compared midkine level in paired cancerous and normal
tissue from patients with colon cancer and found mean
midkine level to be significantly higher in cancerous tissue
(Fig. 1). Except for one case, midkine was higher in tumor
than in normal tissue, i.e., in 98 % of the cases. In 37 out of
51 (72.5 %), the relative increase was over fivefold. Mean
fold increase in midkine level was 30.1 (18.5–41.7).
Midkine level and the disease progression
Midkine level in cancerous tissue is negatively correlated
with tumor size (r0−0.40, p00.017; regression line is pre-
sented in Fig. 2) and shows tendency to positively correlate
with serum midkine concentrations (r00.45, p00.081).
There were no significant differences in midkine level be-
tween T2, T3, and T4 tumors (p00.754), in N0 vs. N1
disease (p00.732), in M0 vs. M1 disease (p00.485), and
among stages I, II, III, and IV (p00.655).
Midkine level and tumor location
We observed higher midkine concentration in normal tissue
derived from rectum [45.5 pg/mg (26.5–78.3) than from colon
(26.2 pg/mg (18.9–36.4), p00.074]. When cancerous tissues
from rectum and colon were compared, no differences in
midkine concentration were found (p00.797). Consequently,
fold increase, i.e., ratio of midkine in cancerous to noncancer-
ous tissue, was significantly higher in colon than in rectum
(Fig. 3). Within colon, however, no difference between prox-
imal and distal part could be observed, both when normal (p0
0.862) or cancerous tissues (p00.839) were compared. The
tendency towards higher fold change in midkine level in
proximal than distal colonic tumors was not significant (45.6
times vs. 33, p00.859).
Midkine level and the disease progression in relation
to tumor location
We re-examined the data by analyzing the fold changes in





















Fig. 1 Midkine level in cancerous and normal colon tissue in patients
with colon cancer. Midkine level is expressed in picograms of midkine
per miligram of total protein (means with 95 % confidence intervals
given in parentheses). Asterisk statistically significant

















Fig. 2 Midkine relation to tumor size (regression line). Data on tumor
size available for 36 patients; two outlying observations removed prior
to analysis. R200.16, p00.017. Thick line regression curve, thinner

























Fig. 3 Differences in fold increase in midkine level between cancerous
and normal tissues in relation to tumor location. Whiskers indicate
95 % confidence interval. Asterisk statistically significant
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fold change in midkine was significantly higher in advanced
stages of rectal cancer, while the opposite trend was ob-
served in colonic cancers (Fig. 4). In addition, fold change
in midkine level was higher in rectal N1 than N0 cancers,
while it tended to be lower in colonic cancers (Fig. 5).
Similar tendency was found concerning T stage, where fold
changes in midkine tended to be higher in T3/T4 than T2
rectal [15.6 (7–24) vs. 7 (0.9–14), p00.152] but not colonic
tumors [37 (18–56) vs. 41 (5.6–77), p00.853]. The number
of patients with M1 disease was insufficient to allow for the
statistical analysis of tumor-location stratified groups.
Difference in midkine association with the disease pro-
gression between rectal and colonic cancers was also ob-
served, although less pronounced, when midkine levels in
cancerous tissue and not fold changes were compared.
Midkine level was significantly higher in advanced stages
of rectal [636.5 pg/mg (314.5–1288) in III/IV vs. 190.8 pg/
mg (62–588) in I/II, p00.036] but not colonic cancers
[respectively 409.5 pg/mg (227–740) vs. 514.5 pg/ml
(308–858), p00.551]. It tended to be higher in N1 vs. N0
disease in rectal [580 pg/mg (266–1265) vs. 264.2 pg/mg
(80–871), p00.180] but not in colonic cancers [375 pg/mg
(212–664) vs. 553 pg/mg (330–928), p 00.301].
Furthermore, midkine level tended to be lower in T3/T4
than T2 colonic tumors [respectively 399 pg/mg (265–
601) vs. 833 pg/mg (475–1459), p00.146] but not rectal
tumors [465 pg/mg (193–1117) vs. 336 pg/mg (98–1151),
p00.606].
Discussion
To best of our knowledge, this is the first paper showing
differences in midkine level as well as in its association
pattern with the disease progression between cancers of
colon and rectum.
Data on midkine in CRC are surprisingly scanty.
Aridome et al. [8] were first to detect, semi-quantitatively,
higher midkine expression in cancerous than noncancerous
tissue from 12 out of 13 CRC patients (>92 %).
Subsequently, Miyashiro et al. [9] confirmed midkine mes-
senger RNA expression in cancerous tissues, either as a full-
size midkine or its truncated form, devoid of its N-terminal
domain. Since the truncated midkine has been found in
cancerous colorectal tissue and in metastatic lymph nodes,
but not in adjacent noncancerous tissue, the cancer-specific
nature of the truncated form has been suggested [10].
Corroborating with these original findings, we found higher
midkine concentration in cancerous than noncancerous tis-
sue in 98 % of examined cases. Owing to the polyclonal
character of the antibody used for midkine detection, we
were likely to detect both full and truncated midkine forms.
Ye et al. [11] and Tokuyama et al. [12] demonstrated
midkine expression to be higher in adenomas and adenocar-
cinomas than in normal mucosa, being significantly elevated
already in low-grade [12] or moderate-grade dysplasia [11].
While Tokuyama et al. [12] observed midkine expression to
increase in a stepwise manner, Ye et al. [11] found the
highest midkine levels in adenomas. Midkine expression
has corresponded with cell proliferative zone, that is, the
labeling of Ki-67, a proliferative index [12]. Taken together,
these results may imply that elevated midkine expression
can contribute to early stages of colon carcinogenesis by
facilitating tumor cell proliferation. The issue of midkine
expression in relation to CRC stage has not been examined
in earlier studies. Supporting the thesis on midkine involve-












































Fig. 4 Fold changes in midkine level between cancerous and normal
tissue in relation to tumor location and the disease stage. Whiskers









































Fig. 5 Fold changes in midkine level between cancerous and normal
tissue in relation to tumor location and lymph node involvement.
Whiskers indicate 95 % confidence interval. Asterisk statistically
significant
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downregulation in advanced cancers, we found a negative
correlation between midkine concentration and tumor size
but did not observed any other association with the disease
advancement. However, further analysis revealed that mid-
kine expression differed with respect to tumor location. Not
only we found midkine to be expressed more profusely in
noncancerous rectal than colonic tissue, but also tumor
location determined midkine association with the disease
stage. Midkine was upregulated in advanced cancers in
rectum, being significantly associated with overall disease
stage and lymph node involvement, but downregulated in
advanced colonic cancers. Previously, Song et al. [15] ob-
served serum midkine to be more frequently elevated in
lymph node positive than negative colon cancers. The asso-
ciation of circulating midkine with lymph node metastasis
has also been demonstrated in esophageal squamous cell
carcinoma [16] and in endometrial cancers [17]. Our results,
if confirmed in a larger cohort, might suggest divergent role
of midkine in colonic and rectal carcinogenesis.
A body of evidence has recently been gathered document-
ing variability in molecular patterns of colorectal cancers
located in various parts of large intestine. Proximal colonic
tumors have been observed to overexpress Ki-67 and p53 [4],
Bcl-2 (solely in female) [4], keratins, and carbonic anhydrases
[18] while in distal colonic tumors COX2 and teratocarcinoma
growth factor [18]. Tumors of proximal colon are also more
likely to be poorly differentiated [4, 5, 19] and associated with
worse overall but not cancer-specific survival [5]. In turn,
Derwinger et al. [5] reported differences within distal colonic
cancers with cancers of sigmoid colon having more favorable
prognosis expressed in terms of overall survival and cancer-
specific survival, resulting from better stage and grade, as
compared to descending colon. Correspondingly, fold change
in midkine in descending colon tumors was higher than in
sigmoid colon tumors, but as we examined only three cases of
the former, the difference did not reached statistical signifi-
cance (45 times vs. 31, data not shown). Minoo et al. [19]
examined differences in expression patterns of 50 markers
associated either with major signaling pathways involved in
tumor progression or with immune response, of which several
were more frequently overexpressed in rectal than other distal
colon cancers (CD44v6, E-cadherin, CD68, CD163, and
Foxp3), while others were found to be differently expressed
in rectal vs. proximal cancers (TOPK, APAF-1, p21, Foxp3,
TIA-1, CDX2, and β-catenin). In turn, Kalady et al. [20]
found a higher incidence of microsatellite instability, methyl-
ator phenotype, and mutations in the oncogene BRAF in
colonic than rectal cancers. Microsatellite stable tumors had
almost four times higher risk of disease recurrence [20], what
may contribute to higher incidence of local disease recurrence
and account for generally worse prognosis characteristic for
rectal cancers. In this respect, higher baseline midkine expres-
sion in rectal mucosa together with a direct midkine
association with disease progression might contribute to this
feature of rectal cancers. It is worth mentioning that midkine
has recently been suggested as the recurrence marker for
desmoid tumors, monoclonal neoplasms that may occur as a
part of familial adenomatosis polyposis [21].
Midkine overexpression is common among solid tumors,
as it may facilitate tumor cell proliferation, survival, and
migration, and enables invasion. As such, midkine might
become a promising target for future directed therapies. A
number of strategies to inhibit midkine expression/signaling
are under investigation [22], and successful suppression of
hepatocellular carcinoma growth by midkine-antisense
oligonucleotide-loaded nanoparticles has already been
reported [23]. However, regional divergence in midkine
expression and, possibly, the role it might play in the disease
progression ought to be taken into account while designing
midkine-directed therapies for CRC.
Taking into account regional differences in midkine level,
relative changes expressed in terms of fold changes rather
than absolute cytokine levels should be evaluated in future
studies. However, it would be of interest to compare mid-
kine level in colonic and rectal tissues from noncancer
patients to address the issue whether higher midkine level
in noncancerous rectal than in colonic mucosa observed in
CRC is disease related.
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